National Pension Service Has $236.83 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

National Pension Service increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.2% during the 2nd quarter, Holdings Channel reports. The firm owned 379,815 shares of the biopharmaceutical company’s stock after purchasing an additional 8,264 shares during the quarter. National Pension Service’s holdings in Regeneron Pharmaceuticals were worth $236,830,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $26,000. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $29,000. Mowery & Schoenfeld Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $29,000. Finally, Trust Co. of Vermont bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $29,000. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on REGN. HSBC increased their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research note on Thursday. Truist Financial upped their price target on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a report on Friday, July 31st. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research report on Tuesday, July 7th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Fourteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $802.18.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: HSBC raised its price target to $920 from $800 and maintained a Buy rating, implying additional upside based on the firm’s assessment of Regeneron’s prospects. HSBC price-target report
• Neutral Sentiment: A Wells Fargo healthcare-conference presentation and transcript offered investors additional management commentary, though the provided report does not identify a specific new catalyst. Wells Fargo healthcare conference transcript
• Neutral Sentiment: A report showing zero short interest is likely incomplete or erroneous, because it also reports a zero-day short-interest ratio and an undefined percentage change; it provides little actionable information for investors.
• Negative Sentiment: Several law firms repeated notices about a securities class action against Regeneron, with a September 14, 2026 lead-plaintiff deadline. The lawsuit concerns alleged failures to disclose risks surrounding the Phase 3 Fianlimab-Libtayo trial for melanoma, including statistical and protocol issues and possible effects of FDA Optimus-related amendments on progression-free-survival analysis. The allegations have not been proven. REGN class-action deadline notice
• Negative Sentiment: Reports that American Century Investments sold Regeneron shares may add to concerns about institutional conviction, although the available coverage does not provide the size or timing of the sale. American Century Investments sale report

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at $512,550. This represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,146 shares of company stock worth $3,432,488 in the last ninety days. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Trading Down 1.8%

Regeneron Pharmaceuticals stock opened at $793.26 on Friday. The firm has a market capitalization of $81.67 billion, a price-to-earnings ratio of 19.61, a P/E/G ratio of 1.58 and a beta of 0.20. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $859.34. The firm has a 50 day moving average of $752.38 and a 200 day moving average of $720.15. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the previous year, the firm earned $12.81 EPS. The firm’s revenue was up 16.7% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were issued a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.